EOLS
Evolus Inc (EOLS)
Healthcare • NASDAQ • $6.36-0.47%
- Symbol
- EOLS
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Price
- $6.36
- Daily Change
- -0.47%
- Market Cap
- $418.84M
- Trailing P/E
- N/A
- Forward P/E
- 23.85
- 52W High
- $10.62
- 52W Low
- $3.86
- Analyst Target
- $14.67
- Dividend Yield
- N/A
- Beta
- 1.29
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Company websiteResearch EOLS on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.